The latest biotech news - Labiotech.eu

Home News and Trends Page 50

Latest Posts

NLS Days Malmo 2022

News and Trends 20 Dec 2022

Watch: Sigrid CEO talks about lifestyle diseases

Sigrid Therapeutics AB was founded in 2014 by Tore Bengtsson and Sana Alajmovic, with the vision of transforming the way modern day chronic lifestyle diseases are treated and prevented. The company’s research dates back to 2008 when Bengtsson and his research group at the Department of Molecular Biosciences at Stockholm University in Sweden made discoveries […]

December 20, 2022 - 1 minutemin - By Jim Cornall

malmomassan Malmö

News and Trends 20 Dec 2022

Watch: IRLAB CEO Richard Godfrey

IRLAB discovers and develops novel treatments of Parkinson’s disease and other CNS disorders. The company’s most advanced drug candidates, mesdopetam (IRL790) and pirepemat (IRL752), are in phase IIb and are designed to treat some of the most difficult symptoms related to Parkinson’s disease. In 2021, Ipsen, a specialty pharma company, acquired exclusive global rights to […]

December 20, 2022 - 1 minutemin - By Jim Cornall

malmomassan Malmö

News and Trends 20 Dec 2022

Watch: Mendus interview

Mendus AB is a Swedish company dedicated to changing the course of cancer treatment by addressing tumor recurrence and improving survival outcomes for cancer patients, while preserving quality of life. The company leverages its expertise in allogeneic dendritic cell biology to develop an advanced clinical pipeline of novel, off-the-shelf, cell-based immunotherapies which combine clinical efficacy […]

December 20, 2022 - 3 minutesmins - By Jim Cornall

solid tumor tumour

News and Trends 20 Dec 2022

Ori Biotech and Inceptor Bio partner on solid tumor cell therapy

Cell and gene therapy (CGT) company Ori Biotech, and cell therapy firm Inceptor Bio have announced a new partnership. The deal will utilize Ori Biotech’s manufacturing platform technology to support initial process development through scale-up for manufacturing of Inceptor’s novel CAR-M, CAR-T and CAR-NK programs. Inceptor Bio is the third partner to join Ori’s LightSpeed […]

December 20, 2022 - 2 minutesmins - By Jim Cornall

COPD lung disease chronic obstructive pulmonary disease

News and Trends 20 Dec 2022

Verona Pharma drug meets COPD phase 3 trial endpoints

Verona Pharma plc has announced positive results of its phase 3 ENHANCE-1 trial evaluating nebulized ensifentrine for the maintenance treatment of chronic obstructive pulmonary disease (COPD). The ENHANCE-1 trial successfully met its primary and key secondary endpoints demonstrating significant improvements in lung function, symptoms and quality of life measures. In addition, ensifentrine substantially reduced the […]

December 20, 2022 - 2 minutesmins - By Jim Cornall

DNA, DNA double-helix

News and Trends 20 Dec 2022

Ribbon Biolabs milestone to lead to 2023 market entry

DNA synthesis company Ribbon Biolabs has announced the successful implementation of its InfiniSynth platform for the automated assembly of sequence-agnostic and long DNA. The company achieved the milestone in collaboration with HighRes Biosolutions, a laboratory automation technology company. The InfiniSynth platform enables Ribbon Biolabs to enter the market in 2023 with a highly differentiated approach […]

December 20, 2022 - 2 minutesmins - By Jim Cornall

ADVERTISEMENT

Pancreatic Cancer

News and Trends 20 Dec 2022

iOnctura raises €17.5M for pancreatic cancer therapy

iOnctura BV, a clinical-stage biotech developing novel cancer therapies, has been granted €17.5 million ($18.6 million) funding from the European Investment Council’s (EIC) accelerator program to develop IOA-289 for pancreatic cancer. The EIC’s funding consists of a grant of €2.5 million ($2.7 million), and €15 million ($16 million) of equity investment. Earlier this month, iOnctura […]

December 20, 2022 - 2 minutesmins - By Jim Cornall

fungi fungal infections Scopulariopsis brevicaulis

News and Trends 20 Dec 2022

F2G looks for FDA new drug application approval for invasive fungal infections treatment

F2G Inc. has announced that the U.S. Food and Drug Administration (FDA) has accepted for filing its new drug application (NDA) for olorofim for the treatment of invasive fungal infections in patients who have limited or no treatment options. F2G has requested approval of the NDA under the Limited Population Pathway for Antibacterial and Antifungal […]

December 20, 2022 - 3 minutesmins - By Jim Cornall

malmomassan Malmö

News and Trends 19 Dec 2022

Watch: InfraLife supports Sweden’s life sciences industry

InfraLife (Infra Access for Life Science Sweden) is a Swedish initiative to maximize the benefits of Sweden’s large scale research infrastructures SciLifeLab, MAX IV and ESS. Funded by Swedish Research Council, InfraLife also partners with industrial organizations SwedenBIO & LIF and collaborates with SWElife, MedTech4Health and Swedish MedTech. The intent of the project is to […]

December 19, 2022 - 2 minutesmins - By Jim Cornall

malmomessan Malmö

News and Trends 19 Dec 2022

Watch: Pharm Assist at NLS Days

Pharm Assist is a consultancy company in Sweden offering regulatory affairs services for pharmaceutical and medical device companies. Founded in 1996, Pharm Assist employs more than 20 experts and has assisted more than 250 Nordic and international companies with their regulatory requirements. It acts as partner in product development, authoring and compilation of dossiers for […]

December 19, 2022 - 1 minutemin - By Jim Cornall

Greece Greek flag

News and Trends 19 Dec 2022

Watch: Biotech in Greece

Greece was one of the countries exhibiting at Bio-Europe, held in Leipzig, Germany. Greece isn’t necessarily well known for biotech, but it has good infrastructure, is located at a crossroads between Europe and Africa and the Middle East, and has excellent universities. And its biotech industry is certainly growing. Enterprise Greece spearheaded the biotech presence […]

December 19, 2022 - 1 minutemin - By Jim Cornall

Leipzig Messe Germany

News and Trends 19 Dec 2022

Watch: Atriva Therapeutics at BIO-Europe

Atriva Therapeutics’ mission is to develop an antiviral therapy platform against severe respiratory and systemic diseases with a high unmet medical need induced by RNA viruses, e.g., influenza and COVID-19. The clinical-stage biopharmaceutical company is pioneering the development of host-targeting antiviral therapies, making development of viral resistance unlikely, and thereby significantly contributing to pandemic preparedness. […]

December 19, 2022 - 1 minutemin - By Jim Cornall

ADVERTISEMENT